The company announced the voluntary recall is due to low, out of specification dissolution test results in specific batches of its tetracycline products.
List view / Grid view
acute bacterial skin and skin structure infections
Filter the results
The US FDA have granted the NDA for iclaprim, an antibiotic for a skin condition, Priority Review, with a decision date set for February 2019...